These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1600 related articles for article (PubMed ID: 29615458)
1. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
2. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724 [No Abstract] [Full Text] [Related]
3. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965 [No Abstract] [Full Text] [Related]
4. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
5. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391 [TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
7. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells. Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559 [TBL] [Abstract][Full Text] [Related]
8. Loss of Heterozygosity of Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893 [TBL] [Abstract][Full Text] [Related]
9. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related]
11. Update on PARP Inhibitors in Breast Cancer. Zimmer AS; Gillard M; Lipkowitz S; Lee JM Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491 [TBL] [Abstract][Full Text] [Related]
12. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
13. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564 [TBL] [Abstract][Full Text] [Related]
14. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation. Zhang R; Wang T; Lin J Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453 [TBL] [Abstract][Full Text] [Related]
15. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904 [TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964 [TBL] [Abstract][Full Text] [Related]
17. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272 [TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 testing: therapeutic implications for breast cancer management. Tung NM; Garber JE Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226 [TBL] [Abstract][Full Text] [Related]
19. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752 [TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors Display Differential Efficacy in Models of Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]